2025 Q4 -tulosraportti
66 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,86%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·6 t sittenNovo Nordisk is approaching the upper end of its sales forecast Major bank UBS now assesses that Novo Nordisk is moving towards the best half of its own sales forecast for the year. This occurs ahead of the company's upcoming quarterly report, which is expected on May 6, 2026. Key points from the analysis Positive outlook: - UBS expects a milder view on this year's sales development than previously assumed. Wegovy success in the USA: - The positive assessment is largely due to a promising development in the number of prescriptions issued for the weight-loss drug Wegovy in the American market. New forms: - The analysis points to growth for the product both in injection form and as a pill. Recommendation and price target: - Despite the positive trends, UBS reiterates a "neutral" recommendation for the Novo share, with a price target of 332 kr. Source: - Article from Finans / MarketWire: "Novo Nordisk nærmer sig bedste halvdel af sin salgsprognose, vurderer UBS" (published April 10, 2026).
·6 t sittenBefore I die, I want to log off Shareville one last time. That shall be my last humble wish. I want to walk on my feet through my city Copenhagen – a last walk without graphs, crashes, and comment fields. I want to walk out there in the city, but with Shareville in my head all the time, as if Copenhagen is just an extended candlestick-chart, or like a portfolio in eternal panic and euphoria at the same time – I walk down Istedgade, and every shop looks like a “turnaround story” that never came, down Vesterbrogade, where everyone talks in RSI and FUD, and down into the small sunless side streets, where the doomsday prophets have already been in the comment thread before me – I see the antique shops as dying small caps, yellowed curtains as slowly falling curves, and greasy gas appliances as old “hold”-recommendations from 2017, and I rummage through the book boxes like a trader looking for the bottom – but never buys, because the bottom always moves right after you’ve found it – I see the children in the backyards playing “bull and bear”, shouting stop-loss and all-in at each other, while the mothers lean out of the windows and call them in before the next crash – And I walk through Vesterbro’s streets: Saxogade, Oehlenschlägergade, Kingosgade, and I hear the echo of the same threads: “IT’S CORRECTING NOW!” “BUBBLE!” “LAST CHANCE FOR EXIT!” “I TOLD YOU SO!” and it’s impossible to say if it comes from the market or the people – I go into Café Guldregn, and everyone at the tables are long-term short-sellers on life itself, with coffee that tastes of margin calls and small laughs over others’ unrealized losses – And I continue towards Hovedbanegården, the great Shareville-mecca, where everything is always either heading towards ATH or total collapse, and nothing ever just “goes a bit sideways” in anyone’s consciousness – The drinkers are old “I said crash in 2019”-prophets, the backpackers new FOMO-entrants with backpacks full of hope, and the commuters are daytraders in disguise, who just haven’t opened their depot yet – And I stand there in the middle of it all and feel the same as in the comment thread: nobody listens, everyone shouts, and everyone is right – especially when they’re not – And I understand that the whole city is just one big thread: full of doomsday, rebounds, hope and bitter triumph, where everyone is waiting for the crash – while the market just moves on without them – – thanks for the ride, Turèll
·16 t sittenNice to see that people are still positive and optimistic It is however still held in an iron grip Kr 5 one way or the other
·5 t sittenWhy doesn't he resign if he himself has acknowledged that the roles are a problem..?
·19 t sitten · MuokattuOn 4 February, Danske bank lowered Novo's price target, from 440 to 390 kr. https://www.sydinvest.dk/nyheder/novo-danske-bank-saenker-kursmaal-til-390-kr-fra-440-kr I read 1-2 weeks ago that if DB's price target for Novo were to hold, Novo would need 210,000 weekly prescriptions for the Wegovy pill by the end of the year. My calculation approx. 4,000 per week on average, or 52,000 in week 13, where we were at 77,903. (The last figures we have received) Novo is on its way to raising the lower end of the announced results. UBS price target 332 kr. https://www.nordnet.dk/markedet/nyheder/8dca6395-e9f1-4e52-b677-de3c93956e19 Novo has previously been a "safe haven", but has taken a lot of beating over the last 1.5 years due to disappointing results, so even though there have been several good news recently, it has not risen on them. Most recently yesterday, that Novo can transport their product under more lenient requirements (temperatures in number of hours). When we soon see Eli Lilly's sales figures, we must remember that when Novo entered the market with their pill, it was new. Now this new pill product has been "discussed" for and against for 3 months, before Eli Lilly entered the market, so it might mean that they start with higher sales figures than Novo did. But it will be exciting to follow their figures, versus Novo's. I still believe in Novo and on 6 May, when the figures are presented and future expectations/plans are revealed, I believe that they/we will be rewarded in the share price. Management often gets criticized for this and that, and it's easy to sit and write that they are incompetent and should be replaced. People are frustrated that their "safe" investment, which was supposed to make them millionaires in a week, is suddenly in the red. It's certainly not one's own fault, but Novo management!!! Clearly... I am sure that they work extremely hard every single day to deliver results for us and a lot goes on behind the scenes that we have no idea about. But it's so easy to blame others...
1 päivä sitten1 päivä sittenInvesting in Novo Feels like having dead money
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
66 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,86%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenNovo Nordisk is approaching the upper end of its sales forecast Major bank UBS now assesses that Novo Nordisk is moving towards the best half of its own sales forecast for the year. This occurs ahead of the company's upcoming quarterly report, which is expected on May 6, 2026. Key points from the analysis Positive outlook: - UBS expects a milder view on this year's sales development than previously assumed. Wegovy success in the USA: - The positive assessment is largely due to a promising development in the number of prescriptions issued for the weight-loss drug Wegovy in the American market. New forms: - The analysis points to growth for the product both in injection form and as a pill. Recommendation and price target: - Despite the positive trends, UBS reiterates a "neutral" recommendation for the Novo share, with a price target of 332 kr. Source: - Article from Finans / MarketWire: "Novo Nordisk nærmer sig bedste halvdel af sin salgsprognose, vurderer UBS" (published April 10, 2026).
- ·6 t sittenBefore I die, I want to log off Shareville one last time. That shall be my last humble wish. I want to walk on my feet through my city Copenhagen – a last walk without graphs, crashes, and comment fields. I want to walk out there in the city, but with Shareville in my head all the time, as if Copenhagen is just an extended candlestick-chart, or like a portfolio in eternal panic and euphoria at the same time – I walk down Istedgade, and every shop looks like a “turnaround story” that never came, down Vesterbrogade, where everyone talks in RSI and FUD, and down into the small sunless side streets, where the doomsday prophets have already been in the comment thread before me – I see the antique shops as dying small caps, yellowed curtains as slowly falling curves, and greasy gas appliances as old “hold”-recommendations from 2017, and I rummage through the book boxes like a trader looking for the bottom – but never buys, because the bottom always moves right after you’ve found it – I see the children in the backyards playing “bull and bear”, shouting stop-loss and all-in at each other, while the mothers lean out of the windows and call them in before the next crash – And I walk through Vesterbro’s streets: Saxogade, Oehlenschlägergade, Kingosgade, and I hear the echo of the same threads: “IT’S CORRECTING NOW!” “BUBBLE!” “LAST CHANCE FOR EXIT!” “I TOLD YOU SO!” and it’s impossible to say if it comes from the market or the people – I go into Café Guldregn, and everyone at the tables are long-term short-sellers on life itself, with coffee that tastes of margin calls and small laughs over others’ unrealized losses – And I continue towards Hovedbanegården, the great Shareville-mecca, where everything is always either heading towards ATH or total collapse, and nothing ever just “goes a bit sideways” in anyone’s consciousness – The drinkers are old “I said crash in 2019”-prophets, the backpackers new FOMO-entrants with backpacks full of hope, and the commuters are daytraders in disguise, who just haven’t opened their depot yet – And I stand there in the middle of it all and feel the same as in the comment thread: nobody listens, everyone shouts, and everyone is right – especially when they’re not – And I understand that the whole city is just one big thread: full of doomsday, rebounds, hope and bitter triumph, where everyone is waiting for the crash – while the market just moves on without them – – thanks for the ride, Turèll
- ·16 t sittenNice to see that people are still positive and optimistic It is however still held in an iron grip Kr 5 one way or the other·5 t sittenWhy doesn't he resign if he himself has acknowledged that the roles are a problem..?
- ·19 t sitten · MuokattuOn 4 February, Danske bank lowered Novo's price target, from 440 to 390 kr. https://www.sydinvest.dk/nyheder/novo-danske-bank-saenker-kursmaal-til-390-kr-fra-440-kr I read 1-2 weeks ago that if DB's price target for Novo were to hold, Novo would need 210,000 weekly prescriptions for the Wegovy pill by the end of the year. My calculation approx. 4,000 per week on average, or 52,000 in week 13, where we were at 77,903. (The last figures we have received) Novo is on its way to raising the lower end of the announced results. UBS price target 332 kr. https://www.nordnet.dk/markedet/nyheder/8dca6395-e9f1-4e52-b677-de3c93956e19 Novo has previously been a "safe haven", but has taken a lot of beating over the last 1.5 years due to disappointing results, so even though there have been several good news recently, it has not risen on them. Most recently yesterday, that Novo can transport their product under more lenient requirements (temperatures in number of hours). When we soon see Eli Lilly's sales figures, we must remember that when Novo entered the market with their pill, it was new. Now this new pill product has been "discussed" for and against for 3 months, before Eli Lilly entered the market, so it might mean that they start with higher sales figures than Novo did. But it will be exciting to follow their figures, versus Novo's. I still believe in Novo and on 6 May, when the figures are presented and future expectations/plans are revealed, I believe that they/we will be rewarded in the share price. Management often gets criticized for this and that, and it's easy to sit and write that they are incompetent and should be replaced. People are frustrated that their "safe" investment, which was supposed to make them millionaires in a week, is suddenly in the red. It's certainly not one's own fault, but Novo management!!! Clearly... I am sure that they work extremely hard every single day to deliver results for us and a lot goes on behind the scenes that we have no idea about. But it's so easy to blame others...
- 1 päivä sitten1 päivä sittenInvesting in Novo Feels like having dead money
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
66 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,86%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenNovo Nordisk is approaching the upper end of its sales forecast Major bank UBS now assesses that Novo Nordisk is moving towards the best half of its own sales forecast for the year. This occurs ahead of the company's upcoming quarterly report, which is expected on May 6, 2026. Key points from the analysis Positive outlook: - UBS expects a milder view on this year's sales development than previously assumed. Wegovy success in the USA: - The positive assessment is largely due to a promising development in the number of prescriptions issued for the weight-loss drug Wegovy in the American market. New forms: - The analysis points to growth for the product both in injection form and as a pill. Recommendation and price target: - Despite the positive trends, UBS reiterates a "neutral" recommendation for the Novo share, with a price target of 332 kr. Source: - Article from Finans / MarketWire: "Novo Nordisk nærmer sig bedste halvdel af sin salgsprognose, vurderer UBS" (published April 10, 2026).
- ·6 t sittenBefore I die, I want to log off Shareville one last time. That shall be my last humble wish. I want to walk on my feet through my city Copenhagen – a last walk without graphs, crashes, and comment fields. I want to walk out there in the city, but with Shareville in my head all the time, as if Copenhagen is just an extended candlestick-chart, or like a portfolio in eternal panic and euphoria at the same time – I walk down Istedgade, and every shop looks like a “turnaround story” that never came, down Vesterbrogade, where everyone talks in RSI and FUD, and down into the small sunless side streets, where the doomsday prophets have already been in the comment thread before me – I see the antique shops as dying small caps, yellowed curtains as slowly falling curves, and greasy gas appliances as old “hold”-recommendations from 2017, and I rummage through the book boxes like a trader looking for the bottom – but never buys, because the bottom always moves right after you’ve found it – I see the children in the backyards playing “bull and bear”, shouting stop-loss and all-in at each other, while the mothers lean out of the windows and call them in before the next crash – And I walk through Vesterbro’s streets: Saxogade, Oehlenschlägergade, Kingosgade, and I hear the echo of the same threads: “IT’S CORRECTING NOW!” “BUBBLE!” “LAST CHANCE FOR EXIT!” “I TOLD YOU SO!” and it’s impossible to say if it comes from the market or the people – I go into Café Guldregn, and everyone at the tables are long-term short-sellers on life itself, with coffee that tastes of margin calls and small laughs over others’ unrealized losses – And I continue towards Hovedbanegården, the great Shareville-mecca, where everything is always either heading towards ATH or total collapse, and nothing ever just “goes a bit sideways” in anyone’s consciousness – The drinkers are old “I said crash in 2019”-prophets, the backpackers new FOMO-entrants with backpacks full of hope, and the commuters are daytraders in disguise, who just haven’t opened their depot yet – And I stand there in the middle of it all and feel the same as in the comment thread: nobody listens, everyone shouts, and everyone is right – especially when they’re not – And I understand that the whole city is just one big thread: full of doomsday, rebounds, hope and bitter triumph, where everyone is waiting for the crash – while the market just moves on without them – – thanks for the ride, Turèll
- ·16 t sittenNice to see that people are still positive and optimistic It is however still held in an iron grip Kr 5 one way or the other·5 t sittenWhy doesn't he resign if he himself has acknowledged that the roles are a problem..?
- ·19 t sitten · MuokattuOn 4 February, Danske bank lowered Novo's price target, from 440 to 390 kr. https://www.sydinvest.dk/nyheder/novo-danske-bank-saenker-kursmaal-til-390-kr-fra-440-kr I read 1-2 weeks ago that if DB's price target for Novo were to hold, Novo would need 210,000 weekly prescriptions for the Wegovy pill by the end of the year. My calculation approx. 4,000 per week on average, or 52,000 in week 13, where we were at 77,903. (The last figures we have received) Novo is on its way to raising the lower end of the announced results. UBS price target 332 kr. https://www.nordnet.dk/markedet/nyheder/8dca6395-e9f1-4e52-b677-de3c93956e19 Novo has previously been a "safe haven", but has taken a lot of beating over the last 1.5 years due to disappointing results, so even though there have been several good news recently, it has not risen on them. Most recently yesterday, that Novo can transport their product under more lenient requirements (temperatures in number of hours). When we soon see Eli Lilly's sales figures, we must remember that when Novo entered the market with their pill, it was new. Now this new pill product has been "discussed" for and against for 3 months, before Eli Lilly entered the market, so it might mean that they start with higher sales figures than Novo did. But it will be exciting to follow their figures, versus Novo's. I still believe in Novo and on 6 May, when the figures are presented and future expectations/plans are revealed, I believe that they/we will be rewarded in the share price. Management often gets criticized for this and that, and it's easy to sit and write that they are incompetent and should be replaced. People are frustrated that their "safe" investment, which was supposed to make them millionaires in a week, is suddenly in the red. It's certainly not one's own fault, but Novo management!!! Clearly... I am sure that they work extremely hard every single day to deliver results for us and a lot goes on behind the scenes that we have no idea about. But it's so easy to blame others...
- 1 päivä sitten1 päivä sittenInvesting in Novo Feels like having dead money
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt